Recombinant EBOV/Makona GP nanoparticle vaccine

N/A

Report date: 2022/03/17 11:20:31

Base Information

Drug NameRecombinant EBOV/Makona GP nanoparticle vaccine
Drug Alias NameRecombinant EBOV/Makona Glycoprotein (GP) Nanoparticle VaccineEBOV/MAK GP
ClassificationVaccines > Development/production technology > Recombinant vector vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsHemorrhagic Fever, Ebola
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNovavax
China Registration ClassN/A

Develop Information

Active CompaniesNovavax
Inactive CompaniesN/A
Active IndicationsHemorrhagic Fever, Ebola
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A